Upgrade to SI Premium - Free Trial

Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook

January 25, 2018 6:31 AM

(Updated - January 25, 2018 6:33 AM EST)

Biogen (NASDAQ: BIIB) reported Q4 EPS of $5.26, $0.19 worse than the analyst estimate of $5.45. Revenue for the quarter came in at $3.31 billion versus the consensus estimate of $3.08 billion.

GUIDANCE:

Biogen sees FY2018 EPS of $24.20-$25.20 consensus of $24.16 and revenue of $12.7-13 billion, versus the consensus of $12.68 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

Categories

Earnings Guidance Hot Earnings Hot Guidance

Next Articles